Skip to main content
Clinical Trials/NCT04668521
NCT04668521
Terminated
Not Applicable

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Aspira Women's Health1 site in 1 country215 target enrollmentMay 4, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Adnexal Mass
Sponsor
Aspira Women's Health
Enrollment
215
Locations
1
Primary Endpoint
OVA360
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

Registry
clinicaltrials.gov
Start Date
May 4, 2020
End Date
December 15, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

OVA360

Time Frame: 12 months

Identify the molecular key driver of Ovarian cancer and develop a diagnostic test for early Ovarian cancer detection

Study Sites (1)

Loading locations...

Similar Trials